Literature DB >> 25560183

Usefulness of the log odds of positive lymph nodes to predict and discriminate prognosis in gastric carcinomas.

A Calero1, J Escrig-Sos, F Mingol, A Arroyo, D Martinez-Ramos, M de Juan, J L Salvador-Sanchis, E Garcia-Granero, R Calpena, F J Lacueva.   

Abstract

BACKGROUND: The lymph node ratio (LNR) and log odds of positive lymph nodes (LODDS) have been proposed to minimize the stage migration phenomenon. The value of the LODDS and LNR staging systems to predict and discriminate prognosis was assessed and compared to the International Union Against Cancer (UICC) TNM classification (pN).
METHODS: Three hundred and twenty-six patients with gastric carcinoma were retrospectively studied. Disease-specific survival rates were calculated for every pN, LNR, and LODDS category.
RESULTS: Four LNR categories (0, 1-25, 26-75, and >76 %) and four LODDS categories (-5 to -3, > -3 to -1, > -1 to 3, and >3 to 5) were established. In the multivariate analysis, only the stage pT3-4 versus pT1-2 (HR 1.88, 95 % CI 1.11-3.20, p=0.02) and LODDS as continuous variable (HR 1.40, 95 % CI 1.21-1.61, p<0.001) remained as independent prognostic factors. In patients with <16 lymph nodes retrieved, only the LODDS system could discriminate different disease-specific survival curves for every category. LODDS categories were able to discriminate subgroups with different prognoses in pN stages and LNR categories.
CONCLUSIONS: The LODDS staging system was superior to the pN classification and LNR system to discriminate risk prognosis especially in patients with an insufficient number of retrieved lymph nodes.

Entities:  

Mesh:

Year:  2015        PMID: 25560183     DOI: 10.1007/s11605-014-2728-5

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  26 in total

1.  Surgical results in gastric cancer.

Authors:  J P Kim
Journal:  Semin Surg Oncol       Date:  1999-09

2.  Log odds of positive lymph nodes: a novel prognostic indicator superior to the number-based and the ratio-based N category for gastric cancer patients with R0 resection.

Authors:  Zhe Sun; Yan Xu; De Ming Li; Zhen Ning Wang; Guo Lian Zhu; Bao Jun Huang; Kai Li; Hui Mian Xu
Journal:  Cancer       Date:  2010-06-01       Impact factor: 6.860

3.  Classification of regional lymph node metastasis from gastric carcinoma. German Gastric Cancer Study Group.

Authors:  J D Roder; K Böttcher; R Busch; C Wittekind; P Hermanek; J R Siewert
Journal:  Cancer       Date:  1998-02-15       Impact factor: 6.860

4.  Prognostic assessment of different metastatic lymph node staging methods for gastric cancer after D2 resection.

Authors:  Jia Xu; Yu-Hai Bian; Xin Jin; Hui Cao
Journal:  World J Gastroenterol       Date:  2013-03-28       Impact factor: 5.742

5.  The RML of lymph node metastasis was superior to the LODDS for evaluating the prognosis of gastric cancer.

Authors:  Honggen Liu; Jingyu Deng; Rupeng Zhang; Xishan Hao; Xuguan Jiao; Han Liang
Journal:  Int J Surg       Date:  2013-03-27       Impact factor: 6.071

6.  Extended lymph-node dissection for gastric cancer.

Authors:  J J Bonenkamp; J Hermans; M Sasako; C J van de Velde; K Welvaart; I Songun; S Meyer; J T Plukker; P Van Elk; H Obertop; D J Gouma; J J van Lanschot; C W Taat; P W de Graaf; M F von Meyenfeldt; H Tilanus
Journal:  N Engl J Med       Date:  1999-03-25       Impact factor: 91.245

7.  Appraisal of compliance with the UICC/AJCC staging system in the staging of gastric cancer. Union Internacional Contra la Cancrum/American Joint Committee on Cancer.

Authors:  P J Mullaney; M S Wadley; C Hyde; J Wyatt; G Lawrence; M T Hallissey; J W L Fielding
Journal:  Br J Surg       Date:  2002-11       Impact factor: 6.939

8.  The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients.

Authors:  Alberto Marchet; Simone Mocellin; Alessandro Ambrosi; Paolo Morgagni; Domenico Garcea; Daniele Marrelli; Franco Roviello; Giovanni de Manzoni; Annamaria Minicozzi; Giovanni Natalini; Francesco De Santis; Luca Baiocchi; Arianna Coniglio; Donato Nitti
Journal:  Ann Surg       Date:  2007-04       Impact factor: 12.969

9.  The tumor-log odds of positive lymph nodes-metastasis staging system, a promising new staging system for gastric cancer after D2 resection in China.

Authors:  Miao-zhen Qiu; Hui-juan Qiu; Zhi-qiang Wang; Chao Ren; De-shen Wang; Dong-sheng Zhang; Hui-yan Luo; Yu-hong Li; Rui-hua Xu
Journal:  PLoS One       Date:  2012-02-14       Impact factor: 3.240

10.  Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group.

Authors:  A Cuschieri; S Weeden; J Fielding; J Bancewicz; J Craven; V Joypaul; M Sydes; P Fayers
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

View more
  13 in total

1.  Superiority of log odds of positive lymph nodes (LODDS) for prognostic prediction after gastric cancer surgery: a multi-institutional analysis of 7620 patients in China.

Authors:  Pengfei Gu; Jingyu Deng; Zhe Sun; Zhenning Wang; Wei Wang; Han Liang; Huimian Xu; Zhiwei Zhou
Journal:  Surg Today       Date:  2020-08-04       Impact factor: 2.549

2.  Comparison of different lymph node staging schemes in prostate cancer patients with lymph node metastasis.

Authors:  Shengming Jin; Junjie Wang; Yijun Shen; Hualei Gan; Peihang Xu; Yu Wei; Jiaming Wei; Junlong Wu; Beihe Wang; Jun Wang; Chen Yang; Yao Zhu; Dingwei Ye
Journal:  Int Urol Nephrol       Date:  2019-09-24       Impact factor: 2.370

3.  Prognostic Role of Log Odds of Lymph Nodes After Resection of Pancreatic Head Cancer.

Authors:  Hartwig Riediger; Birte Kulemann; Uwe Wittel; Ulrich Adam; Olivia Sick; Hannes Neeff; Jens Höppner; Ulrich T Hopt; Frank Makowiec
Journal:  J Gastrointest Surg       Date:  2016-07-06       Impact factor: 3.452

4.  The Prognostic Ability of Log Odds of Positive Lymph Nodes in Oral Cavity Squamous Cell Carcinoma.

Authors:  Ching-Chih Lee; Hsu-Chueh Ho; Yu-Chieh Su; Moon-Sing Lee; Shih-Kai Hung; Yen-Lin Chen
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

5.  Prognostic value of three different lymph node staging systems in the survival of patients with gastric cancer following D2 lymphadenectomy.

Authors:  Chen Jian-Hui; Cai Shi-Rong; Wu Hui; Chen Si-le; Xu Jian-Bo; Zhai Er-Tao; Chen Chuang-Qi; He Yu-Long
Journal:  Tumour Biol       Date:  2016-02-24

6.  Comparison of prognostic nomograms based on different nodal staging systems in patients with resected gastric cancer.

Authors:  Zi-Xian Wang; Miao-Zhen Qiu; Yu-Ming Jiang; Zhi-Wei Zhou; Guo-Xin Li; Rui-Hua Xu
Journal:  J Cancer       Date:  2017-03-12       Impact factor: 4.207

7.  Development and validation of a novel staging system integrating the number and location of lymph nodes for gastric adenocarcinoma.

Authors:  Ziyu Li; Xiaolong Wu; Xiangyu Gao; Fei Shan; Xiangji Ying; Yan Zhang; Jiafu Ji
Journal:  Br J Cancer       Date:  2020-12-02       Impact factor: 7.640

8.  Number of evaluated lymph nodes and positive lymph nodes, lymph node ratio, and log odds evaluation in early-stage pancreatic ductal adenocarcinoma: numerology or valid indicators of patient outcome?

Authors:  G Lahat; N Lubezky; F Gerstenhaber; E Nizri; M Gysi; M Rozenek; Y Goichman; I Nachmany; R Nakache; I Wolf; J M Klausner
Journal:  World J Surg Oncol       Date:  2016-09-29       Impact factor: 2.754

9.  Lymph node staging systems in patients with gastric cancer treated with D2 resection plus adjuvant chemotherapy.

Authors:  Yi-Xin Zhou; Lu-Ping Yang; Zi-Xian Wang; Ming-Ming He; Jing-Ping Yun; Dong-Sheng Zhang; Feng Wang; Rui-Hua Xu
Journal:  J Cancer       Date:  2018-01-06       Impact factor: 4.207

10.  Log odds of positive lymph nodes is prognostically equivalent to lymph node ratio in non-metastatic colon cancer.

Authors:  Ali Riaz Baqar; Simon Wilkins; Wei Wang; Karen Oliva; Paul McMurrick
Journal:  BMC Cancer       Date:  2020-08-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.